Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 11/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | HTR5A | P47898 | 1/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041391 | 1.00 | NCF1 (1.00) | NCF1ADRB2ADRB1HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL30061214 | 0.98 | NCF1 (0.97) | NCF1ADRB2ADRB1HTR6HTR1A | |
| SCHEMBL23412205 | 0.94 | NCF1 (0.88) | NCF1ADRB2ADRB1HTR6HTR1A | |
| SCHEMBL2884262 | 0.89 | NCF1 (0.79) | NCF1ADRB2ADRB1HTR6HTR1A | |
| SCHEMBL30061245 | 0.87 | NCF1 (0.77) | NCF1ADRB2ADRB1HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL3711412 | 0.87 | NCF1 (0.77) | NCF1ADRB2ADRB1HTR6HTR1A | |
| SCHEMBL14515644 | 0.84 | NCF1 (0.73) | NCF1ADRB2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL3649189 | 0.84 | NCF1 (0.73) | NCF1ADRB2TSHRHSD17B10KDM4E | |
| SCHEMBL19000048 | 0.83 | NCF1 (0.71) | NCF1ADRB2TSHRHSD17B10KDM4E | |
| SCHEMBL28250832 | 0.83 | NCF1 (0.71) | NCF1ADRB2HSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4139291-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | MBD CO., LTD (KR) | 2022-12-22 | — | — | US | disclosed |
| CN-115427404-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022235091-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | 엠비디 주식회사 | 2022-11-10 | — | — | WO | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021096335-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | 엠비디 주식회사 | 2021-05-20 | — | — | WO | disclosed |
| US-5627196-A | ANTIDEPRESSANTS AND ANTISEROTONIN AGENTS | ELI LILLY AND COMPANY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5614523-A | INDOLYLOXY COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| US-5576321-A | ALKOXY-SUBSTITUTED INDOLES | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| WO-1996022290-A1 | COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0722941-A2 | Compounds having effects on serotonin-related systems | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | NCF1 2417/4885ADRB2 916/4885ADRB1 492/4885 |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | NCF1 90/4885ADRB2 4640/4885ADRB1 3532/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | NCF1 2221/4885ADRB2 288/4885ADRB1 127/4885 |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | CYP4A11, CYP4B1, CYP4A22 | NCF1 2403/4885ADRB2 1242/4885ADRB1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.